MNK
Mallinckrodt Plc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Market Cap: 4.52 Million
Primary Exchange: NYSE MKT LLC
Website: http://www.mallinckrodt.com/
Shares Outstanding: 13.3 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: -0.41810422510582074
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1921 trading days
From: 2015-03-18 To: 2023-08-25
Lowest Point:
Mallinckrodt's Acthar Gel successful in Phase 4 rheumatoid arthritis study
via: SeekingAlpha at 2019-06-13 03:09:53:000
A Phase 4 clinical trial evaluating Mallinckrodt's (NYSE: MNK ) Acthar Gel (repository corticotropin injection) in patients with patients with persistently active rheumatoid arthritis (RA) who were previously treated with disease-modifying anti-rheumatic drugs (DMARDs) and corticosteroids … read more...
All Primary and Secondary Outcome Targets Met in Mallinckrodt's Phase 4 Acthar® Gel (Repository Corticotropin Injection) Rheumatoid Arthritis (RA) Clinical Trial (n=259) with Data Presented at the European Congress of Rheumatology 2019 (EULAR)
via: PR Newswire at 2019-06-13 02:45:00:000
STAINES-UPON-THAMES, United Kingdom , June 13, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global specialty biopharmaceutical company, is reporting that all primary and secondary outcome measures were met in its Phase 4, multicenter study assessing the efficacy and … read more...
Teva hits 19-year low on continued pricing pressure
via: SeekingAlpha at 2019-06-12 06:49:59:000
Teva Pharmaceutical Industries ( TEVA -4.2% ) slumps on modestly higher volume. Shares are now exchanging hands at the lowest prices in 19 years. The stock continues to fight pricing headwinds, the continued erosion of Copaxone sales (down 56% in Q1) and its potential exposure from opioid … read more...
Barclays bearish on Teva, sees 14% downside risk in premarket analyst action
via: SeekingAlpha at 2019-06-11 04:46:44:000
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more … read more...
Mallinckrodt to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference
via: PR Newswire at 2019-06-11 02:55:00:000
STAINES-UPON-THAMES, United Kingdom , June 11, 2019 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 25, 2019 , at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference at the Ma… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|